Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Psoriasis Vulgaris: early-phase trial registry

2 of 7 indexed Psoriasis Vulgaris trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 2 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Psoriasis Vulgaris: 7 US clinical trials tracked, 2 recruiting.

Psoriasis Vulgaris is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 2 of these trials.

Enrollment posture brief

Registry condition psoriasis-vulgaris

OPEN 2 | RECR 29% | LATE 2 | EARLY 4 | RANK #2497 | SPON 2

Nearest open-share peer: Acromegaly (29% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Psoriasis Vulgaris (this)29%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Psoriasis Vulgaris

Psoriasis Vulgaris lists 2 open slots (29% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Psoriasis Vulgaris on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Psoriasis Vulgaris is recruiting below its size-band peers.

    2 of 7 indexed trials (28.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Psoriasis Vulgaris research.

    Bristol-Myers Squibb accounts for 2 of 7 trials (28.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Psoriasis Vulgaris trials plan to enrol fewer than 100 people.

    Median target enrolment is 32 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.

  4. Psoriasis Vulgaris research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22Phase 31Phase 41

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Psoriasis Vulgaris records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

CTLA4Ig / Abatacept Drug
1 trials
Calcipotriene plus betamethasone dipropionate ointment Drug
1 trials
Blue light phototherapy Device
1 trials
injection of botulinum toxin type A. Biological
1 trials
Total coumarin (TC) cream Drug
1 trials
deucravacitinib Drug
1 trials
Abatacept Drug
1 trials
Vehicle cream Drug
1 trials

US sites by state

Facility locations filed on Psoriasis Vulgaris trials. A trial with sites in several states counts in each.

California 4 trials
Illinois 3 trials
Texas 2 trials
Washington 1 trials
Vermont 1 trials
Virginia 1 trials
Utah 1 trials
Pennsylvania 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Psoriasis Vulgaris page

7 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Psoriasis Vulgaris condition card totals 7 registered trials; most-linked intervention CTLA4Ig / Abatacept; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.